Hypertrophic Cardiomyopathy: Analyzing a Historical Series

75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. 

Miocardiopatía hipertrófica: análisis de una serie histórica

There is also alcohol septal ablation as an alternative strategy, which different studies have found favorable, even though its true benefit remains unclear, as well as the group of patients that would benefit from this treatment.  

The study looked at patients undergoing surgical septal myectomy and alcohol septal ablation (ASA) since 1998 to 2019 at the Mayo Clinic and the Fuwai Hospital. In all, it included 3274 patients undergoing septal myectomy and 585 ASA.

Primary end point was all cause mortality.

The ASA patients were older, had more hypertension, diabetes, kidney failure and heart disease, but had smaller septal thickness (19 mm vs 20 mm p=0.007) and no difference in gradient. 

At 30 days, mortality resulted similar: 0.7% vs 0.3% for ASA and septal myectomy respectively.

Read also: ACC 2022 | VALOR-HCM: Mavacamten in Adults with Symptomatic Obstructive HCM Eligible for Septal Reduction Therapy.

At 10 years, primary end point was higher in patients who had received ASA (26.1% vs. 8.2%), which was maintained after adjusting for variables such as age, sex and comorbidities (HR: 1.68; 95% CI: 1.29-2.19; P < 0.001).

Other parameters associated to mortality were functional class III-IV, obstructive pulmonary disease, stroke, atrial fibrillation, renal failures, diabetes and septal thickness, 

Conclusion

In patients with hypertrophic cardiomyopathy, alcohol septal ablation is associated with higher mortality in the long term, regardless other known factors, even though it might be affected by confounding factors overlooked as patient characteristics. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org .

Original Title: Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive. Hypertrophic Cardiomyopathy.

Reference: Hao Cui, et al. (J Am Coll Cardiol 2022;79:1647–1655).


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...